| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | VACWR088 |
| Uniprot No | P07612 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-250aa |
| 氨基酸序列 | MGAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNLTVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPKQVAGTGVQFYMIVIGVIILAALFMYYAKRMLFTSTNDKIKLILANKENVHWTTYMDTFFRTSPMVIATTDMQN |
| 预测分子量 | 27,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为模拟生成的关于VACWR088重组蛋白的参考文献示例(非真实文献，仅供格式参考)：
1. **文献名称**：Structural characterization of VACWR088 recombinant protein in vaccinia virus assembly
**作者**：Smith J, et al.
**摘要**：本研究解析了VACWR088重组蛋白的晶体结构，发现其通过C端结构域与病毒膜蛋白相互作用，在痘苗病毒粒子组装中起关键作用，为痘病毒载体改造提供了理论依据。
2. **文献名称**：Functional analysis of VACWR088 in host immune evasion
**作者**：Li X, et al.
**摘要**：通过基因敲除实验证实VACWR088蛋白能抑制宿主NF-κB信号通路，揭示了其在逃逸天然免疫应答中的新功能，为开发减毒疫苗株提供了潜在靶点。
3. **文献名称**：VACWR088-expressing recombinant vaccinia virus as a novel cancer vaccine platform
**作者**：Garcia R, et al.
**摘要**：构建了表达VACWR088与肿瘤抗原融合蛋白的重组痘苗病毒，在小鼠模型中显示增强的CD8+ T细胞应答和抗肿瘤效果，证明了其作为疫苗载体的应用潜力。
4. **文献名称**：Comparative proteomics of VACWR088 orthologs in orthopoxviruses
**作者**：Chen H, et al.
**摘要**：通过比对正痘病毒属中VACWR088同源蛋白的进化保守性，发现其核心功能域在病毒跨物种传播中可能发挥重要作用，为抗病毒药物设计提供了新方向。
---
**说明**：以上为模拟生成内容，实际文献需通过PubMed、Web of Science或Google Scholar等平台，以"VACWR088"、"vaccinia virus protein"等关键词检索。建议结合研究具体方向(如结构、免疫调控、应用等)细化搜索策略。
VACWR088 is a recombinant protein derived from the vaccinia virus (VACV), a member of the *Poxviridae* family. Vaccinia virus, best known for its role as the live vaccine that eradicated smallpox, has a large double-stranded DNA genome encoding approximately 200 open reading frames (ORFs). VACWR088 corresponds to one of these ORFs, located in the viral genome's conserved core region, which is critical for viral replication and host interaction. The protein is expressed during the early to intermediate stages of infection and is implicated in modulating host immune responses, though its precise mechanistic role remains under investigation.
Recombinant VACWR088 is typically produced using heterologous expression systems, such as *E. coli* or insect cells, to enable biochemical and functional studies. The protein is often purified via affinity tags (e.g., His-tag) and characterized for structural and functional properties. Studies suggest it may interact with host cell pathways involved in innate immunity, potentially inhibiting pro-inflammatory signaling or interfering with antiviral defense mechanisms. This aligns with poxviral strategies to evade immune detection, a feature critical for viral persistence.
Research on VACWR088 contributes to understanding poxvirus pathogenesis and host-pathogen interactions. Its recombinant form serves as a tool for structural studies (e.g., crystallography or cryo-EM) to map functional domains and for antibody generation. Additionally, it may hold relevance in vaccine development, as poxvirus vectors are widely used in recombinant vaccine platforms. Further characterization of VACWR088 could uncover novel targets for antiviral therapies or enhance the safety profile of vaccinia-based vaccines by attenuating immune-modulatory functions. Despite progress, gaps remain in fully elucidating its role in viral replication cycles or systemic immune evasion.
×
